What were the key outcomes of Pfizer's 2011 Annual Shareholder Meeting?

The key outcomes include the re-election of all director nominees, ratification of KPMG LLP as the independent auditor, and approval of executive compensation on an advisory basis. The company also determined that future advisory votes on executive compensation will be held annually.

Did shareholders express concerns about executive compensation?

While the advisory vote on executive compensation was approved, the number of votes against it (2,422,993,133) compared to votes for approval (3,082,645,956) suggests that a significant portion of shareholders had reservations or concerns regarding the compensation structure.

Which shareholder proposals were rejected by the shareholders?

Shareholder proposals concerning the publication of political contributions, public policy initiatives, pharmaceutical price restraints, action by written consent, special shareholder meetings, and animal research did not receive majority approval from the shareholders.

What is the significance of the broker non-votes?

Broker non-votes represent shares held by brokers or nominees that did not receive voting instructions from the beneficial owners. The significant number of broker non-votes in the director elections and executive compensation advisory vote (1,029,664,119) indicates a substantial portion of shares that did not directly influence the outcome of those specific proposals.

PFE 8-K: Shareholder Matters

Summary

Pfizer Inc. (PFE) filed an 8-K report on May 3, 2011, detailing the results of its Annual Meeting of Shareholders held on April 28, 2011. The report indicates strong shareholder support for the election of all director nominees and the ratification of KPMG LLP as the independent registered public accounting firm for 2011. Investors can take comfort in the overwhelmingly positive votes on these fundamental corporate governance matters. However, the results also reveal a mixed sentiment regarding executive compensation, with the advisory vote receiving majority approval but with a significant portion of votes against. Furthermore, several shareholder proposals concerning political contributions, public policy, pharmaceutical pricing, and corporate governance actions like written consent and special meetings, did not receive majority approval, suggesting shareholder alignment with the current management and board approach on these specific issues.

Key Highlights

1All director nominees for Pfizer Inc. were overwhelmingly elected for a one-year term.
2Shareholders ratified the appointment of KPMG LLP as the company's independent registered public accounting firm for 2011 with substantial approval.
3An advisory vote to approve executive compensation received majority support, but with a notable number of dissenting votes.
4Shareholders voted to hold advisory votes on executive compensation on an annual basis.
5Several shareholder proposals, including those on political contributions, public policy, and pharmaceutical price restraints, did not pass.
6Shareholder proposals related to action by written consent and special shareholder meetings also failed to gain majority support.

PFIZER INC 8-K Report, Shareholder Vote Results (May 3, 2011)

Summary

Key Highlights

Frequently Asked Questions